Skip to main content

Table 1 Patient characteristics

From: Mediating effects of self-stigma and depression on the association between autistic symptoms and recovery in patients with schizophrenia-spectrum disorders: a cross-sectional study

  Total samples (N = 105) Outpatients (N = 55, 52.3%) Inpatients (N = 50, 47.7%) p-value
Sex (male/female)a 48/57 22/33 26/24 0.244
Age (mean ± SD) b 47.0 ± 13.3 47.8 ± 14.2 46.1 ± 12.4 0.529
Diagnosisa
 Schizophrenia 103 54 48 1
 Schizoaffective disorder 2 0 2  
 Delusional disorder 1 1 0  
 Age of onset (mean ± SD) b 28.8 ± 11.5 30.2 ± 11.7 27.3 ± 11.1 0.156
 Duration of hospitalization (at time of assessment, mean ± SD, days) 53.0 ± 66.0   53.0 ± 66.0  
 Number of hospitalizations b 4.0 ± 5.1 3.5 ± 4.7 4.7 ± 5.5 0.528
Years of educationa 0.912
  ≤ 9 36 18 18  
  > 9- ≤ 12 36 20 16  
  > 12 32 17 15  
Marital statea
 Single 71 34 37 0.372
 Married 20 13 7  
 Divorced 14 8 6  
 Widow 1 1 0  
Partnersa
 Yes 84 45 39 0.635
 No 21 10 11  
 Antipsychotic medicationb
Antipsychotic dose
(SGA + FGA) (CP equivalent, mean ± SD, mg/day)
617.2 ± 349.9 558.1 ± 360.0 682.2 ± 323.0 0.67
 Antipsychotic dose of SGA (CP equivalent, mean ± SD, mg/day) 582.8 ± 337.5 533.2 ± 352.8 637.4 ± 316.7 0.114
 Antipsychotic dose of FGA (CP equivalent, mean ± SD, mg/day) 34.9 ± 108.23 24.9 ± 84.6 44.8 ± 129.5 0.351
  1. a Fisher’s exact test p-value for the difference in sex, diagnosis, years of education, marital status, and partners between the two groups
  2. b Unpaired t-test p-value for the difference in age between the two groups
  3. AQ Autism-Spectrum Quotient, CP Chlorpromazine, FGA First-generation antipsychotics, IMSI Internalized Stigma of Mental Illness, QIDS, Quick Inventory of Depressive Symptomatology, RAS Recovery Assessment Scale, SGA Second-generation antipsychotics